La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Arcutis Biotherapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Arcutis Biotherapeutics..

Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni, Catena delle Opzioni

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) reported quarterly earnings of $3.49 per share which beat the analyst consensus estimate of $2.90 by 20.34 percent.

Earnings

Earnings Beats

Earnings Misses

News

PFSI

PennyMac Financial Servs Q3 2024 Adj EPS $3.49 Beats $2.90 Estimate

Bank of N.T Butterfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTB#NYSE">NTB</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.14 by 1.75 percent. The company reported quarterly sales of $142.700 million which beat the analyst consensus estimate of $142.472 million by 0.16 percent. This is a 0.71 percent increase over sales of $141.700 million the same period last year.

Bank of N.T Butterfield Q3 2024 Adj. EPS $1.16 Beats $1.14 Estimate, Sales $142.700M Beat $142.472M Estimate

Biotech

General

ANRO

Alto Neuroscience Announces That The Phase 2b Study Of ALTO-100 In Patients With Major Depressive Disorder Did Not Meet Its Primary Endpoint, Assessed By A Change From Baseline In Montgomery-Åsberg Depression Rating Scale, Compared To Placebo

Argentina has introduced new regulations for the hemp industry through&nbsp;Resolution 1/2024, signed by Ignacio Ferrari, director of the Regulatory Agency for the Hemp and Medicinal Cannabis Industry (ARICCAME). 
These regulations introduce a simplified system that distinguishes between agricultural and industrial activities.
ARICCAME, which oversees hemp and cannabis activities, <a href="https://www.benzinga.com/markets/cannabis/24/09/40926566/argentinas-cannabis-industry-shakeup-will-the-new-government-appointed-comptroller-boost-busines">has been restructured</a> under to resolve operational issues.
The agency&#8217;s new leadership now holds expanded powers to issue licenses and coordinate with other regulatory authorities to ensure compliance with the updated regulations, first <a href="https://elplanteo.com/regulaciones-canamo-licencias-argentina/">reported</a> El Planteo.
<h3 class="wp-block-heading">Argentina's Hemp Potential In the Global Market</h3>
Argentina is already a key player in global agriculture, known for its vast production of commodities like soybeans, meat and corn.
The country's agricultural prowess positions it as a potential major exporter of hemp, offering products like seeds, fibers and oils at competitive prices.
If Argentina's <a href="https://www.google.com/url?sa=t&amp;source=web&amp;rct=j&amp;opi=89978449&amp;url=https://www.benzinga.com/markets/cannabis/24/08/40418137/industrial-hemps-14b-projected-growth-an-investment-opportunity-too-good-to-miss&amp;ved=2ahUKEwiMotKLpaKJAxUuqpUCHabjC6cQFnoECBMQAQ&amp;usg=AOvVaw0tIRFytMtpZRpfLvkTSE66">hemp industry</a> gains momentum, it could drive down global prices and create significant opportunities in international markets, benefiting industries like textiles and pharmaceuticals.
This development could also provide competition to <a href="https://www.benzinga.com/markets/cannabis/24/09/40715126/expert-economist-slashes-hemp-acreage-forecast-by-82-for-2030-heres-why">U.S. hemp producers</a>, as Argentina&#8217;s scale and efficiency may help meet growing global demand at a lower cost.
<ul>
<li>Learn all about Argentina's booming cannabis industry and opportunities ahead at El Planteo's <a href="https://elplanteo.com/eventos/cannab2b/" target="_blank" rel="noreferrer noopener">CannaB2B</a> event in Buenos Aires on November 4. <a href="https://share.hsforms.com/1dzCltrUDRSGMSOTerkComg1npzh?__hstc=99187265.ce2611b4134345745d71884123d3462e.1707500707807.1726678078078.1726684863653.678&amp;__hssc=99187265.1.1726684863653&amp;__hsfp=22530479" target="_blank" rel="noreferrer noopener">Sponsorship opportunities</a> are now open.</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40926566/argentinas-cannabis-industry-shakeup-will-the-new-government-appointed-comptroller-boost-busines">Argentina&#8217;s Cannabis Industry Shakeup: Will The New Government-Appointed Comptroller Boost Business Opportunities?</a>
<h3 class="wp-block-heading">Key Licensing Changes And Fees</h3>
One of the significant updates is the repeal of&nbsp;Resolution No. 2/2023, which governed provisional permits for activities involving cannabis. Existing permits will remain valid until their expiration, but new applications must follow the updated framework.
The new resolution outlines two types of licenses for <a href="https://www.benzinga.com/topic/hemp">industrial hemp</a> production:
<ul>
<li>Agricultural License: Covers cultivation, transportation, and processing of hemp seeds and fiber.
<ul>
<li>0-100 hectares: no cost.</li>
<li>101-500 hectares: $500,000 annually ($550)</li>
<li>501-1000 hectares: $1,000,000 annually ($1100)</li>
<li>More than 1000 hectares: $2,000,000 annually. ($2200)</li>
</ul>
</li>
<li>Industrial License: Governs commercialization, distribution, import, and export of hemp products, with an annual fee of $1,000,000. ($1100)</li>
</ul>
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41371814/guaran-cannabis-lands-in-europe-paraguay-to-export-100-of-its-flower-production">Guaraní Cannabis Lands In Europe: Paraguay To Export 100% Of Its Flower Production</a>
Cover: Benzinga edit based on&nbsp;Photo by <a href="https://unsplash.com/es/@eirhealth?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Eir Health</a>&nbsp;via Unsplash <a href="https://unsplash.com/es/fotos/un-gran-grupo-de-plantas-verdes-en-un-campo-KPoxs_DA500?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener"></a><a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

Cannabis

Markets

Hemp Finally Gets Regulated In Argentina: Will It Boom Like The Country's Many Other Ag Products?

WIIM

TGLS

Tecnoglass shares are trading lower. Sidoti & Co. downgraded the stock from Buy to Neutral and announced a price target of $78.

– Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker –
– ALTO-100 demonstrated a favorable safety and tolerability profile, consistent with previously reported studies –
– Strong cash position expected to fund Alto's planned operations through multiple near-term milestones across pipeline of independent programs –
Alto Neuroscience, Inc. ("Alto") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANRO#NYSE">ANRO</a>), a clinical stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder (MDD) did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo. The favorable safety and tolerability profile of ALTO-100 was consistent with previously reported studies.

Alto Neuroscience Reports Topline Results From A Phase 2b Trial Evaluating ALTO-100 As A Treatment For Major Depressive Disorder; Says  Treatment With ALTO-100 Did Not Demonstrate Improvement In Depressive Symptoms Compared To Placebo In Patients With A Memory-based Cognitive Biomarker

Financial giants have made a conspicuous bearish move on RTX. Our analysis of options history for RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) revealed 16 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 68% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $217,787, and 10 were calls, valued at $592,142.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $70.0 to $135.0 for RTX over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for RTX options trades today is 1306.5 with a total volume of 43,194.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for RTX's big money trades within a strike price range of $70.0 to $135.0 over the last 30 days.
<h3>RTX Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629079_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.5</td>
<td>$7.45</td>
<td>$7.5</td>
<td>$125.00</td>
<td>$150.0K</td>
<td>1.2K</td>
<td style="text-align: right;">248</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.25</td>
<td>$11.75</td>
<td>$11.8</td>
<td>$120.00</td>
<td>$94.4K</td>
<td>161</td>
<td style="text-align: right;">80</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.79</td>
<td>$1.5</td>
<td>$1.53</td>
<td>$130.00</td>
<td>$82.1K</td>
<td>5.7K</td>
<td style="text-align: right;">586</td>
</tr>
<tr>
<td>RTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.05</td>
<td>$8.85</td>
<td>$8.95</td>
<td>$125.00</td>
<td>$62.6K</td>
<td>8</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>RTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$57.0</td>
<td>$56.6</td>
<td>$56.6</td>
<td>$70.00</td>
<td>$56.6K</td>
<td>281</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About RTX</h3>
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace and to the defense market. The company operates in three segments: Collins Aerospace, a diversified aerospace supplier; Pratt &amp; Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
<h3>RTX's Current Market Status</h3>
<ul>
<li>With a volume of 5,733,440, the price of RTX is down -0.25% at $125.58. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
<h3>What The Experts Say On RTX</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $130.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on RTX, which currently sits at a price target of $132. 
&#x2A; An analyst from Deutsche Bank upgraded its action to Hold with a price target of $129. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest RTX options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

What the Options Market Tells Us About RTX

Whales with a lot of money to spend have taken a noticeably bullish stance on Etsy.
Looking at options history for Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) we detected 20 trades.
If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish.
From the overall spotted trades, 14 are puts, for a total amount of $1,900,177 and 6, calls, for a total amount of $415,310.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $30.0 to $85.0 for Etsy over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Etsy stands at 1506.79, with a total volume reaching 2,729.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Etsy, situated within the strike price corridor from $30.0 to $85.0, throughout the last 30 days.
<h3>Etsy Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629073_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.5</td>
<td>$21.15</td>
<td>$21.15</td>
<td>$70.00</td>
<td>$926.3K</td>
<td>162</td>
<td style="text-align: right;">532</td>
</tr>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$10.15</td>
<td>$9.75</td>
<td>$9.9</td>
<td>$50.00</td>
<td>$239.5K</td>
<td>1.0K</td>
<td style="text-align: right;">265</td>
</tr>
<tr>
<td>ETSY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$9.9</td>
<td>$9.85</td>
<td>$9.9</td>
<td>$50.00</td>
<td>$228.6K</td>
<td>22</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$21.2</td>
<td>$21.1</td>
<td>$21.1</td>
<td>$70.00</td>
<td>$170.9K</td>
<td>162</td>
<td style="text-align: right;">81</td>
</tr>
<tr>
<td>ETSY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$31.75</td>
<td>$30.6</td>
<td>$31.65</td>
<td>$80.00</td>
<td>$110.7K</td>
<td>105</td>
<td style="text-align: right;">65</td>
</tr>
</tbody>
</table>

<h3>About Etsy</h3>
Etsy operates a top-10 e-commerce marketplace operator in the us and the UK, with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.2 billion in 2023 consolidated gross merchandise volume, Etsy has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2023, the firm connected more than 96 million buyers and 9 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), and Depop (clothing resale).
<h3>Current Position of Etsy</h3>
<ul>
<li>Currently trading with a volume of 2,938,605, the ETSY's price is down by -4.71%, now at $49.33. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 8 days.</li>
</ul>
<h3>What Analysts Are Saying About Etsy</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $55.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $76. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Etsy, targeting a price of $58. 
&#x2A; An analyst from Goldman Sachs has revised its rating downward to Sell, adjusting the price target to $45. 
&#x2A; An analyst from Wells Fargo persists with their Underweight rating on Etsy, maintaining a target price of $47. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $50. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Etsy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ETSY

Etsy Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bullish approach towards Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MU usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 82 extraordinary options activities for Micron Technology. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 45% bearish. Among these notable options, 30 are puts, totaling $3,427,719, and 52 are calls, amounting to $2,969,808.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $150.0 for Micron Technology over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Micron Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Micron Technology's substantial trades, within a strike price spectrum from $60.0 to $150.0 over the preceding 30 days.
<h3>Micron Technology Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729629068_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$26.35</td>
<td>$26.25</td>
<td>$26.35</td>
<td>$130.00</td>
<td>$524.3K</td>
<td>564</td>
<td style="text-align: right;">400</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$26.15</td>
<td>$25.95</td>
<td>$26.15</td>
<td>$130.00</td>
<td>$523.0K</td>
<td>564</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$11.3</td>
<td>$11.25</td>
<td>$11.3</td>
<td>$92.50</td>
<td>$223.7K</td>
<td>411</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.55</td>
<td>$21.45</td>
<td>$21.45</td>
<td>$120.00</td>
<td>$214.5K</td>
<td>3.0K</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.85</td>
<td>$21.45</td>
<td>$21.45</td>
<td>$120.00</td>
<td>$214.5K</td>
<td>3.0K</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Micron Technology</h3>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
In light of the recent options history for Micron Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Micron Technology Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 12,654,811, the MU's price is down by -1.27%, now at $107.69. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 57 days.</li>
</ul>
<h3>Professional Analyst Ratings for Micron Technology</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $132.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Micron Technology with a target price of $150. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Micron Technology, targeting a price of $114. 
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Micron Technology with a target price of $140. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Micron Technology, which currently sits at a price target of $125. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Micron Technology, targeting a price of $135. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Micron Technology, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Micron Technology

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock rose 21.4% to $0.78 during Tuesday's after-market session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares increased by 11.7% to $1.05. The market value of their outstanding shares is at $17.8 million. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares rose 8.49% to $2.17. The market value of their outstanding shares is at $162.7 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares rose 6.68% to $18.99. The company's market cap stands at $1.7 billion. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) stock rose 6.15% to $2.76. The market value of their outstanding shares is at $95.3 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock rose 5.26% to $0.44. The company's market cap stands at $7.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) shares declined by 15.7% to $2.1 during Tuesday's after-market session. The market value of their outstanding shares is at $51.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares declined by 11.45% to $0.48. The company's market cap stands at $6.6 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock decreased by 10.59% to $3.21. The market value of their outstanding shares is at $8.3 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock declined by 6.72% to $1.25. The market value of their outstanding shares is at $111.0 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) shares declined by 6.71% to $0.58. The company's market cap stands at $14.5 million. </li>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock decreased by 6.67% to $4.9. The market value of their outstanding shares is at $205.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALLK

CNTX

ENSC

FTRE

GNLX

GNPX

HURA

NDRA

PTIX

SNSE

TELA

TLPH

12 Health Care Stocks Moving In Tuesday's After-Market Session

GATX

GATX shares are trading higher after the company reported better-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Farmmi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) stock moved upwards by 147.6% to $0.78 during Tuesday's after-market session. The market value of their outstanding shares is at $8.3 million. </li>
<li>Australian Oilseeds Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOT#NASDAQ">COOT</a>) stock increased by 28.04% to $1.05. The market value of their outstanding shares is at $24.3 million. </li>
<li>Blue Star Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) shares moved upwards by 4.01% to $0.62. The company's market cap stands at $1.5 million. </li>
<li>Reborn Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>) shares rose 3.99% to $2.34. The market value of their outstanding shares is at $9.3 million. </li>
<li>Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) stock moved upwards by 3.82% to $2.11. The company's market cap stands at $1.3 billion. </li>
<li>Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) stock increased by 3.22% to $1.6. The market value of their outstanding shares is at $21.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Chanson International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares decreased by 8.2% to $11.0 during Tuesday's after-market session. The market value of their outstanding shares is at $235.4 million. </li>
<li>Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) shares declined by 4.76% to $56.09. The market value of their outstanding shares is at $19.9 billion. </li>
<li>Maison Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) stock declined by 4.54% to $1.05. The company's market cap stands at $20.6 million. </li>
<li>Real Good Food Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) shares fell 4.38% to $0.35. The market value of their outstanding shares is at $6.8 million. </li>
<li>Top Wealth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) stock declined by 3.36% to $9.5. The company's market cap stands at $532.0 million. </li>
<li>Upexi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares decreased by 2.68% to $4.0. The market value of their outstanding shares is at $4.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSFC

CHSN

COOT

FAMI

FLGC

Merrill Lynch & Strategic Return Notes for Select 10 Index

OLPX

REBN

UPXI

12 Consumer Staples Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) shares rose 9.8% to $47.69 during Tuesday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q3 earnings came out today. </li>
<li>Turbo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TURB#NASDAQ">TURB</a>) stock increased by 5.52% to $1.72. The company's market cap stands at $18.9 million. </li>
<li>FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares rose 4.99% to $0.66. The company's market cap stands at $84.8 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock moved upwards by 3.51% to $0.23. The market value of their outstanding shares is at $9.0 million. </li>
<li>Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) shares moved upwards by 3.12% to $1.39. The company's market cap stands at $6.4 million. </li>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares moved upwards by 2.88% to $1.0. The company's market cap stands at $18.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock fell 12.2% to $0.21 during Tuesday's after-market session. The company's market cap stands at $10.6 million. </li>
<li>noco-noco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) shares declined by 5.58% to $0.13. The company's market cap stands at $25.5 million. </li>
<li>New Horizon Aircraft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) stock decreased by 4.33% to $0.33. The market value of their outstanding shares is at $7.9 million. </li>
<li>JE Cleantech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCSE#NASDAQ">JCSE</a>) stock fell 3.98% to $1.45. The market value of their outstanding shares is at $7.2 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) stock declined by 3.51% to $1.93. The market value of their outstanding shares is at $1.7 million. </li>
<li>Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) shares fell 3.51% to $63.4. The market value of their outstanding shares is at $6.5 billion. The company's, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTCI

GPUS

GRFX

HOVR

ILAG

JCSE

KITT

NCNC

STAF

TURB

VICR

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Zapata Computing Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZPTA#NASDAQ">ZPTA</a>) shares moved upwards by 29.6% to $0.08 during Tuesday's after-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) shares moved upwards by 15.59% to $4.3. The company's market cap stands at $41.5 million. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) shares rose 11.05% to $0.43. The market value of their outstanding shares is at $11.2 million. </li>
<li>CCSC Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) stock rose 7.14% to $1.8. The company's market cap stands at $20.8 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares moved upwards by 6.85% to $0.97. The market value of their outstanding shares is at $36.8 million. </li>
<li>Oblong (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBLG#NASDAQ">OBLG</a>) stock moved upwards by 5.77% to $4.03. The market value of their outstanding shares is at $4.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares decreased by 13.5% to $2.05 during Tuesday's after-market session. The company's market cap stands at $12.6 million. </li>
<li>Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) shares fell 8.67% to $267.0. The market value of their outstanding shares is at $16.3 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) stock decreased by 7.85% to $84.99. The company's market cap stands at $11.5 billion. As per the press release, Q3 earnings came out today. </li>
<li>Focus Universal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) shares declined by 4.84% to $0.26. The market value of their outstanding shares is at $17.7 million. </li>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) shares fell 4.7% to $1.6. The company's market cap stands at $4.1 million. </li>
<li>U-BX Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares fell 3.96% to $0.4. The market value of their outstanding shares is at $11.8 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBB

BNAI

BTCT

CCTG

ENPH

FCUV

MANH

OBLG

UBXG

ZPTA

12 Information Technology Stocks Moving In Tuesday's After-Market Session

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 61.29% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 38.16% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 20.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 17.86% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 14.29% at $4.98</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 13.24% at $3.55</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 12.57% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 12.38% at $2.25</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 9.80% at $6.10</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.97% at $1.70</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">Cansortium</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 7.97% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 7.97% at $11.11</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 7.61% at $1.71</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 7.47% at $13.30</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 7.39% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 6.47% at $2.15</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 5.42% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 4.23% at $2.29</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.43% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 3.16% at $0.27</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GEATF">Radiko Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GEATF#OTC">GEATF</a>) shares closed down 90.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/BMMJ">Body and Mind</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BMMJ#OTC">BMMJ</a>) shares closed down 20.11% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 15.22% at $1.62</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 12.52% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 9.89% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 7.69% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 7.22% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 6.14% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 5.58% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 3.69% at $0.52</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 3.44% at $86.75</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBRRF

BMMJ

CARA

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CNTMF

CRLBF

CRON

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

CXXIF

ELLXF

GEATF

GTBIF

LMLLF

MRMD

OILFF

RMHB

RSSFF

SNDL

SOLCF

TCNNF

TLRY

UGRO

XXII

ZDPY

Marijuana Stock Movers For October 22, 2024

Cannabis Stock Movers For October 22, 2024

OCUP

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

BIVI

BioVie shares are trading higher. The company closed its registered direct offering and concurrent private placement.

Orrstown Finl Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) reported quarterly earnings of $1.11 per share which beat the analyst consensus estimate of $0.92 by 20.65 percent. This is a 27.59 percent increase over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $51.70 million which beat the analyst consensus estimate of $49.23 million by 5.01 percent. This is a 97.17 percent increase over sales of $26.22 million the same period last year.

ORRF

Orrstown Finl Servs Q3 Adj $1.11 Beats $0.92 Estimate, Sales $51.70M Beat $49.23M Estimate

TELA Bio shares are trading lower after the company began its public offering of common stock and pre-funded warrants.

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Align Tech (ALGN – Research Report) and Arcutis Biot...

Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN) and Arcutis Biotherapeutics (ARQT)

Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely

Arcutis surges 18% as Mizuho highlights growth of Zoryve

Arcutis Biotherapeutics (ARQT) has received a new Buy rating, initiated by Jefferies analyst, Kambiz Yazdi. Kambiz Yazdi has given his Buy rating d...

Buy Rating Initiated on Arcutis Biotherapeutics Amidst Zoryve's Market Expansion and Promising Sales Trajectory

With recent top-and-bottom-line beats, biotech Arcutis Biotherapeutics ($ARQT) continues to grab attention as demand for its recently approved trea...

Arcutis Biotherapeutics (ARQT) Riding High on Psoriasis Treatment

Vikram Purohit, an analyst from Morgan Stanley, maintained the Buy rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price...

Buy Rating Affirmed for Arcutis Biotherapeutics Amid Positive Dermatology Market Signals

Arcutis' supplemental application for Zoryve accepted by FDA

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bioxcel Therapeutics (BTAI – Research Report) and ...

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Arcutis Biotherapeutics (ARQT)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report) on October 11. The company's shares cl...

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report) and...

Wall Street Analysts Are Bullish on Top Healthcare Picks

ALGN

ARQT

BTAI

COCH

INCY

ROIV

Health Care

Press Releases

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analyst Ratings

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Comments

Arcutis Biotherapeutics

Arcutis Biotherapeutics (ARQT) Opzioni

Arcutis Biotherapeutics (NASDAQ:ARQT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO